Zai Lab Limited ADR Dossier - Source-backed chat

Zai Lab Limited ADR

ZLABNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.85

Intrinsic Value $37.38median of 2 methodsbased on filings through 30 Jun 2026

Market Price $26.34Price as of 30 Sep 2026

UndervaluedIntrinsic value is 42% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $3B

Enterprise Value $2.6B

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Zai Lab is navigating a transitional phase in 2026, characterized by near-term revenue headwinds on its mature commercial products in China (ZEJULA and VYVGART) due to volume-based procurement and NRDL pricing resets. However, the company's long-term investment thesis remains highly compelling, driven by its dual-engine strategy. Zai Lab is rapidly advancing its wholly owned global oncology asset, zocilurtatug pelitecan (zoci), which has demonstrated standout clinical efficacy in SCLC and neuroendocrine carcinomas. Backed by a robust cash position of $761.3 million and strategic collaborations with global leaders like Amgen and Boehringer Ingelheim, Zai Lab is well-positioned to transition into a global biopharmaceutical innovator. Near-term commercial catalysts, including the Q2 2026 launch of KarXT in China and the potential approval of TIVDAK, provide additional layers of regional growth.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets12 analysts · as of 18 Aug 2026

Low · most bearish analyst$24.25

Mean target$32.18

High · most bullish analyst$50.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$24.25

In the bear case, competitive pressures in China's PARP inhibitor market intensify further, and generic generic olaparib erosion of ZEJULA sales is more severe than anticipated. Supply constraints for newer products like XACDURO persist longer than expected, delaying commercial ramp-up. On the clinical front, zoci's registrational trials face enrollment delays, pushing back the anticipated 2027 interim analysis. Additionally, the ongoing shareholder class action investigations regarding bemarituzumab lead to costly litigation, depressing investor sentiment.

Base CaseCentral scenario

$32.18

Matches the consensus mean

The base case assumes Zai Lab experiences continued revenue pressure throughout 2026, with sequential product revenue improvements over the next nine months leading to a return to year-over-year growth in 2027. Zoci's registrational trials remain on track to complete enrollment in H1 2027, and the company successfully launches KarXT in Q2 2026. R&D and SG&A expenses remain elevated to support pipeline advancement, but the company's $761.3 million cash runway remains highly sufficient, keeping the long-term growth trajectory intact.

Bull CaseUpside scenario

$50.00

In the bull case, zocilurtatug pelitecan (zoci) achieves rapid enrollment in its registrational DLLEVATE trial, leading to outstanding interim efficacy data and accelerated FDA approval ahead of schedule. Simultaneously, the commercial launch of KarXT in China exceeds expectations, capturing significant market share in schizophrenia, while VYVGART volume growth rapidly offsets the NRDL pricing discount. Strong execution across the pipeline and commercial portfolio drives a return to robust revenue growth by late 2026, significantly ahead of consensus expectations.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Standout clinical data for lead global asset zocilurtatug pelitecan (zoci) in SCLC and epNECs, supported by global clinical collaborations with Amgen and Boehringer Ingelheim.
Robust balance sheet with $761.3 million in cash, cash equivalents, and short-term investments as of March 31, 2026, providing a strong financial runway.
Near-term commercial catalysts in China, including the Q2 2026 launch of KarXT (first novel schizophrenia mechanism in decades) and the pending regulatory approval of TIVDAK.
Highly experienced management team executing a validated dual-engine strategy that bridges China commercialization with global innovation.

Key Investment Risks

Near-term revenue pressure in 2026 due to volume-based procurement impacts on ZEJULA and NRDL pricing adjustments on VYVGART.
Supply chain and manufacturing constraints, particularly for XACDURO, which could limit near-term sales execution.
Intense competition in the oncology and immunology markets in China from both multinational corporations and local generic players.
Clinical development and regulatory risks associated with late-stage global trials, as highlighted by the diminished survival advantage in the final analysis of the FORTITUDE-101 trial.

Thesis Invalidation Triggers

Failure of zocilurtatug pelitecan (zoci) to meet its primary endpoints in the registrational DLLEVATE trial or safety concerns emerging in combination studies.
A prolonged delay in the commercial launch or poor market uptake of KarXT in China.
Significant acceleration of cash burn that reduces the company's funding runway to less than 18 months without a clear path to profitability.
Adverse regulatory decisions by the China NMPA or US FDA on key pipeline assets.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.